Warfarin sodium
- CAS No.
- 129-06-6
- Chemical Name:
- Warfarin sodium
- Synonyms
- VITAMIN K2;athrombin;panwarfin;WARFARIN SODIUM SALT;3-(ALPHA-ACETONYLBENZYL)-4-HYDROXYCOUMARIN;SODIUM 4-OXO-3-(3-OXO-1-PHENYL-BUTYL)-CHROMEN-2-OLATE;waran;varfine;marevan;tintorane
- CBNumber:
- CB7346095
- Molecular Formula:
- C19H15O4.Na
- Molecular Weight:
- 330.31
- MDL Number:
- MFCD00083223
- MOL File:
- 129-06-6.mol
- MSDS File:
- SDS
| Melting point | approximate 161℃ |
|---|---|
| alpha | ±0° |
| storage temp. | 2-8°C |
| solubility | Very soluble in water and in ethanol (96 per cent), soluble in acetone, very slightly soluble in methylene chloride. |
| color | White to Almost white |
| PH | pH (10g/l, 25℃) : 7.2～8.3 |
| Merck | 14,10038 |
| BCS Class | 1,2 |
| CAS DataBase Reference | 129-06-6(CAS DataBase Reference) |
| FDA UNII | 6153CWM0CL |
| NCI Drug Dictionary | Panwarfin |
| EPA Substance Registry System | Sodium warfarin (129-06-6) |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |   GHS06,GHS08 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Danger | |||||||||
| Hazard statements | H300-H360-H412 | |||||||||
| Precautionary statements | P202-P264-P270-P273-P280-P301+P310 | |||||||||
| Hazard Codes | T+ | |||||||||
| Risk Statements | 61-28 | |||||||||
| Safety Statements | 53-36/37/39-45-36/37-28 | |||||||||
| RIDADR | UN 1544 6.1/PG 2 | |||||||||
| WGK Germany | 1 | |||||||||
| RTECS | GN4725000 | |||||||||
| HazardClass | 6.1(a) | |||||||||
| PackingGroup | II | |||||||||
| HS Code | 29322090 | |||||||||
| Toxicity | LD50 in male rats, female rats, mice, rabbits (mg/kg): 323, 58, 374, ~800 orally (Hagen); also reported as LD50 in male, female rats (mg/kg): 100.3, 8.7 orally (Back) | |||||||||
| NFPA 704 |
|
Warfarin sodium price More Price(24)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich | PHR1435 | Warfarin Sodium Pharmaceutical Secondary Standard; Certified Reference Material | 129-06-6 | 1g | $105 | 2024-03-01 | Buy |
| Sigma-Aldrich | A4571 | 3-(α-Acetonylbenzyl)-4-hydroxycoumarin sodium salt ≥98% | 129-06-6 | 10g | $274 | 2024-03-01 | Buy |
| TCI Chemical | W0005 | Warfarin Sodium (contains Isopropyl Alcohol) >98.0%(HPLC) | 129-06-6 | 5g | $66 | 2024-03-01 | Buy |
| TCI Chemical | W0005 | Warfarin Sodium (contains Isopropyl Alcohol) >98.0%(HPLC) | 129-06-6 | 25g | $195 | 2024-03-01 | Buy |
| Sigma-Aldrich | W0100000 | Warfarin sodium European Pharmacopoeia (EP) Reference Standard | 129-06-6 | w0100000 | $220 | 2024-03-01 | Buy |
Warfarin sodium Chemical Properties,Uses,Production
Chemical Properties
Colorless solid
Originator
Coumadin ,Endo,US,1954
Uses
central stimulant
Uses
Rodenticide.
Uses
Warfarin Sodium (Crystalline Clathrate) is used for pharmaceutical care for patients with chronic heart failure and renal dysfunction.
Manufacturing Process
About 0.1 mol each of 4-hydroxycoumarin and benzalacetone are dissolved, in
any desired order, in about three times their combined weight of pyridine. The
solution is refluxed for about 24 hours, and then allowed to cool; after which
it is poured into about 15 volumes of water, and acidified to about pH 2 by the
addition of hydrochloric acid. An oil separates, and on cooling and standing
overnight solidifies. The solid product is recovered, as by filtration, and
recrystallized from ethanol, according to US Patent 2,427,578.
The base melts at about 161°C. It is a white crystalline solid, soluble in hot
ethyl alcohol and substantially insoluble in cold water; it dissolves in alkali
solutions with formation of the salt. The yield is about 40%.
Then, as described in US Patent 2,777,859, warfarin may be reacted with
NaOH to give a sodium salt solution. Crystalline warfarin sodium may be
prepared as described in US Patent 2,765,321.
brand name
Athrombin (Purdue Frederick); Coumadin (Bristol-Myers Squibb); Jantoven (USl); Panwarfin (Abbott).
Therapeutic Function
Anticoagulant
General Description
Warfarin sodium, 3-( -acetonylbenzyl)-4-hydroxycoumarin sodium salt (Coumadin,Panwarfin), is a white, odorless, crystalline powder, with aslightly bitter taste; it is slightly soluble in chloroform and solublein alcohol or water. A 1% solution has a pH of 7.2 to 8.5.
General Description
Slightly bitter crystalline powder. An anticoagulant used as a rodenticide.
Reactivity Profile
A coumarin derivative, a lactone. Lactones are similar to esters reactive chemistries.
Health Hazard
Warfarin sodium is highly toxic orally in humans.
Fire Hazard
When heated to decomposition, Warfarin sodium emits toxic fumes of sodium oxide.
Clinical Use
By virtue of its great potency, warfarin sodium at firstwas considered unsafe for use in humans and was used veryeffectively as a rodenticide, especially against rats. At theproper dosage level, however, it can be used in humans, especiallythrough the intravenous route.
Safety Profile
Poison to humans by ingestion. Experimental poison by ingestion and intravenous routes. Human systemic effects by ingestion: dermatitis. Human reproductive effects by ingestion: fetotoxicity, abnormal condition of newborn at birth, other newborn physical effects, and teratogenic effects includmg developmental abnormalities of the eye and ear, craniofacial area, skin and appendages, musculoskeletal system, cardiovascular system, and gastrointestinal system of the fetus. ,4n experimental teratogen. Other experimental reproductive effects. Mutation data reported. An anticoagulant drug. When heated to decomposition it emits toxic fumes of Na2O.
Veterinary Drugs and Treatments
In veterinary medicine, warfarin is used primarily for the oral, long-term treatment (or prevention of recurrence) of thrombotic conditions, primarily in cats, dogs, or horses. Use of warfarin in veterinary species is somewhat controversial and due to unproven benefit in reducing mortality, increased expense associated with monitoring, and potential for serious effects (bleeding), many do not recommend its use.
Drug interactions
Potentially hazardous interactions with other drugs
There are many significant interactions with warfarin.
Prescribe with care with regard to the following:
Anticoagulant effect enhanced by: alcohol,
amiodarone, anabolic steroids, aspirin, aztreonam,
bicalutamide, cephalosporins, chloramphenicol,
cimetidine, ciprofloxacin, clopidogrel, cranberry
juice, danazol, danshen, dipyridamole, dronedarone,
disulfiram, entacapone, esomeprazole, exenatide,
ezetimibe, fibrates, fluconazole, flutamide, fluvastatin,
glucosamine, grapefruit juice, itraconazole,
ketoconazole, levamisole, levofloxacin, macrolides,
methylphenidate, metronidazole, miconazole,
mirtazepine, nalidixic acid, neomycin, norfloxacin,
NSAIDs, ofloxacin, omeprazole, pantoprazole,
paracetamol, penicillins, proguanil, propafenone,
ritonavir, rosuvastatin, saquinavir, SSRIs, simvastatin,
sulfinpyrazone, sulphonamides, tamoxifen, tegafur,
testosterone, tetracyclines, thyroid hormones,
tigecycline, toremifene, tramadol, trimethoprim,
valproate, venlafaxine, vitamin E and voriconazole.
Anticoagulant effect decreased by: acitretin,
atorvastatin, azathioprine, barbiturates,
carbamazepine, enteral feeds, eslicarbazepine,
enzalutamide, fosphenytoin, ginseng, griseofulvin,
oral contraceptives, phenobarbital, phenytoin,
primidone, rifamycins, St John’s wort (avoid
concomitant use), sucralfate, vitamin K.
Anticoagulant effects enhanced / reduced by: anion
exchange resins, atazanavir, corticosteroids, dietary
changes, disopyramide, efavirenz, fosamprenavir,
nevirapine, ritonavir, telaprevir, tricyclics, trazodone.
Analgesics: increased risk of bleeding with IV
diclofenac and ketorolac - avoid concomitant use.
Anticoagulants: increased risk of haemorrhage with
apixaban, dabigatran, edoxaban and rivaroxaban -
avoid concomitant use.
Antidiabetic agents: enhanced hypoglycaemic
effect with sulphonylureas; also possible changes to
anticoagulant effect.
Camomile: enhanced anticoagulation.
Ciclosporin: there have been a few reports of altered
anticoagulant effect; decreased ciclosporin levels have
been seen rarely.
Cytotoxics: increased risk of bleeding with erlotinib,
imatinib and regorafenib; enhanced effect with
capecitabine, etoposide, fluorouracil, ifosfamide,
gefitinib, gemcitabine, sorafenib and vemurafenib;
reduced effect with mercaptopurine and mitotane.
Melatonin: possibly enhanced INR.
Metabolism
The R- and S-isomers are both metabolised in the liver. The
S-isomer is metabolised more rapidly than the R-isomer,
mainly by the cytochrome P450 isoenzyme CYP2C9, which
shows genetic polymorphism. Other isoenzymes are also
involved in the metabolism of the R-isomer.
The metabolites, which have negligible or no
anticoagulant activity, are excreted in the urine following
reabsorption from the bile.
Dose in renal impairment G
Warfarin sodium Preparation Products And Raw materials
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Hebei Yanxi Chemical Co., Ltd. | +8617531190177 | peter@yan-xi.com | China | 5857 | 58 |
| Wuhan Fortuna Chemical Co., Ltd | +86-027-59207850 | info@fortunachem.com | China | 5975 | 58 |
| Hebei Weibang Biotechnology Co., Ltd | +8617732866630 | bess@weibangbio.com | China | 18150 | 58 |
| Henan Bao Enluo International TradeCo.，LTD | +86-17331933971 +86-17331933971 | deasea125996@gmail.com | China | 2472 | 58 |
| airuikechemical co., ltd. | +undefined86-15315557071 | sales02@sdzhonghuimaterial.com | China | 983 | 58 |
| Henan Tianfu Chemical Co.,Ltd. | +86-0371-55170693 +86-19937530512 | info@tianfuchem.com | China | 21634 | 55 |
| ATK CHEMICAL COMPANY LIMITED | +undefined-21-51877795 | ivan@atkchemical.com | China | 32957 | 60 |
| Hefei TNJ Chemical Industry Co.,Ltd. | +86-0551-65418679 +8618949832763 | info@tnjchem.com | China | 2986 | 55 |
| career henan chemical co | +86-0371-86658258 +8613203830695 | sales@coreychem.com | China | 29880 | 58 |
| SHANDONG ZHI SHANG CHEMICAL CO.LTD | +86 18953170293 | sales@sdzschem.com | China | 2930 | 58 |
View Lastest Price from Warfarin sodium manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2024-12-13 | Warfarin sodium
129-06-6
|
US $0.00 / Kg/Bag | 1KG | 97.0%~102.0%; USP41 | 1500kg/month | WUHAN FORTUNA CHEMICAL CO., LTD | |
 |
2024-11-14 | Warfarin sodium
129-06-6
|
US $415.00 / Kg/Bag | 1KG | 99% | 1T | Baoji Guokang Bio-Technology Co., Ltd. | |
 |
2024-10-28 | Warfarin sodium
129-06-6
|
US $0.00 / KG | 1KG | 99% | 500000kg | Hebei Weibang Biotechnology Co., Ltd |
-
- Warfarin sodium
129-06-6
- US $0.00 / Kg/Bag
- 97.0%~102.0%; USP41
- WUHAN FORTUNA CHEMICAL CO., LTD
-
- Warfarin sodium
129-06-6
- US $415.00 / Kg/Bag
- 99%
- Baoji Guokang Bio-Technology Co., Ltd.
-
- Warfarin sodium
129-06-6
- US $0.00 / KG
- 99%
- Hebei Weibang Biotechnology Co., Ltd